Furthermore, recent research has demonstrated that ARID1A-deficient cancer cells have low levels of glutathione due to the decreased expression of SLC7A11 and are specifically vulnerable to the inhibition of the antioxidant glutathione and glutamate-cysteine ligase synthetase catalytic subunit, a rate-limiting enzyme for glutathione synthesis [89]. The gene discussed is ARID1A; the disease is cancer.